Amylyx Pharmaceuticals, Inc. Increase (Decrease) in Inventories
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase (Decrease) in Inventories of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-03-03
- Amylyx Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2024 was $9.25M, a 87.35% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2023 was $73.13M, a 648.58% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2022 was $9.77M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $9.25M 10-K · filed 2026-03-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $9.25M 10-Q · filed 2025-11-06 | $35.73M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $9.25M 10-Q · filed 2025-08-07 | $35.73M derived: sum of 3 quarters · filed 2025-08-07 | $49.75M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.25M 10-Q · filed 2025-05-08 | $35.73M derived: sum of 2 quarters · filed 2025-05-08 | $49.75M derived: sum of 3 quarters · filed 2025-05-08 | $69.08M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $26.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $40.49M derived: sum of 2 quarters · filed 2025-03-04 | $59.83M derived: sum of 3 quarters · filed 2025-03-04 | $73.13M 10-K · filed 2025-03-04 |
| 2023-09-30 | $14.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $33.34M derived: sum of 2 quarters · filed 2024-11-07 | $46.65M 10-Q · filed 2024-11-07 | $55.85M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $19.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $32.64M 10-Q · filed 2024-08-08 | $41.84M derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $13.30M 10-Q · filed 2024-05-09 | $22.51M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $9.77M 10-K · filed 2024-02-22 | ||
| 2022-09-30 | $563.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |